DeirdreJillCohenMD

PubMed

• 769 citations
  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
  Smruti Pushalkar, Mautin Hundeyin, Donnele Daley, Constantinos P. Zambirinis, Emma Kurz
  Cancer Discovery. 2018-04-01
• 7 citations
  Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.
  Fionnuala Crowley, Sonal Gandhi, Michelle Rudshteyn, Mantej Sehmbhi, Deirdre J Cohen
  The Oncologist. 2023-06-02
• 19 citations
  Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection.
  Abhishek Pandey, Deirdre J Cohen
  Immunotherapy. 2020-04-06

Journal Articles

• Targeting the Hedgehog Pathway: Role in Cancer and Clinical Implications of its Inhibition  
  Cohen DJ, Hematology/Oncology Clinics of North America, 6/1/2012
• Postoperative intraperitoneal 5-fluoro-2’-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal j...  
  Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter HL, Hochster H, Muggia F, Annals of Surgical Oncology, 2/1/2012
• Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors  
  Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS, Cancer Chemotherapy and Pharmacology, 8/1/2011
• An expert opinion on esophageal cancer therapy  
  Cohen DJ and Ajani J, Expert Opinion on Pharmacotherapy, 2/1/2011
• Treatment Paradigms with Epidermal Growth Factor Receptor-Targeted Therapies in Colorectal Cancer  
  Stein S, Cohen DJ, and Hochster H, Clinical Colorectal Cancer, 1/1/2010
• Rationale for Combining Biotherapy in the Treatment of Advanced Colon Cancer  
  Cohen DJ and Hochster H, Gastrointestinal Cancer Research, 1/1/2008
•  
  Vahdat LT, Cohen DJ, Zipin D, Lo KS, Frederick D, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS, Bone Marrow Transplantation, 8/1/2007
• Update on Clinical Data with Regimens Inhibiting Angiogenesis and Epidermal Growth Factor Receptor for Patients with Newly Diagnosed Metastatic Colorectal Caner  
  Cohen DJ and Hochster H, Clinical Colorectal Cancer, 1/1/2007
• Join now to see all

Books/Book Chapters

• New Treatment Strategies for Metastatic Colorectal Cancer 
  Chapter: Second-Line Treatment of Metastatic Colorectal Cancer: Chemotherapy with Integration of Biologic Agents- Review of Current Data. 
  Page 47 - 68Cohen DJ and Hochster HSEditors: Edward Chu.New Haven, CT2008

Abstracts/Posters

• A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.
  Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, Skoble J, Lemmens ..., J Clin Oncol, 1/1/2014
• Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (G...
  Cohen DJ, Christos PJ, Kindler HL, Catenacci DV, Bekaii-Saab T, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Take..., J Clin Oncol, 1/1/2013
• The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
  Hochster HS, Messersmith WA, O'Neil BH, Groshen SG, Lenz H, Cohen DJ, Denlinger CS, Gold PJ, Eckhardt SG, Locker GY, Ames P, McKinley M, Leichman L, Academic GI Cancer..., J Clin Oncol, 1/1/2013
• Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.
  Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, Skoble J, Lemmens ..., J Clin Oncol, 1/1/2013
• A randomized phase II study of vismodegib, a hedgehog pathway inhibitor, combined with FOLFOX in patients with advanced gastric and gastroesophageal junction carcinoma...
  Cohen DJ, Christos P, Sparano J, Kindler H, Catenacci D, Bekaii-Saab T, Tahiri S, Janjigian Y, Gibson M, Chan E, Rajdev L, Urba S, Wade J, Kozuch P, Love E, Vandris K,..., J Clin Oncol, 1/1/2012
• Mucinous neoplasms of the appendix: A single-center experience.
  Guo S, Barry M, Hajdu C, Cohen DJ, J Clin Oncol, 1/1/2012
• Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with iri...
  Hochster H, Messersmith W, O'Neil B, Groshen S, Cohen DJ, Denlinger C, Gold P, Eckhardt G, Locker G, Ames P, McKinley M, Leichman L, Academic GI Cancer Consortium, J Clin Oncol, 1/1/2012
• Quantitative expression of the hedgehog (Hh) signaling pathway in gastric carcinoma: A novel protocol to process RNA from paraffin-embedded tissue.
  Akalu A., Liebes L, Xu R, Schneider R, Takebe N, Cohen DJ, American Association for Cancer Research (AACR) Symposium, 1/1/2011
• A Phase I/II Study of induction oxaliplatin and 5FU chemo-radiation.
  Melis M, Ryan T, Hochster H, Cohen DJ, Masi A, Chandra A, Pachter HL, Newman E, Digestive Disease Week, 1/1/2011
• Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
  Cohen DJ, Leichman LP, Love E, Ryan T, Leichman GC, Newman E, Levinson B, Hochster H, Journal of Clinical Oncology 2011 Gastrointestinal Cancers Symposium, 1/1/2011
• A randomized, double-blind-placebo-controlled phase II study of FOLFOX with or without GDC-0049 (vismodegib) in patients with advanced gastric and gastroesophageal jun...
  Cohen DJ, Liebes L, Xu R, Takebe N, Sparano JA, J Clin Oncol, 1/1/2011
• Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation.
  Ma H, Yuan Y, Ryan T, Newman E, Cohen DJ, Choi H, Hochster HS, ASCO Gastrointestinal Cancers Symposium, 1/1/2009
• Activity and tolerance of biweekly CapeOx-Cetuximab in first-line therapy of metastatic colorectal cancer (mCRC) and K-ras influences.
  Yuan Y, Ma H, Cohen DJ, Ryan T, Choi H, Love E, Awad M, Khambata-Ford S, Mauro D, Hochster HS, ASCO Gastrointestinal Cancers Symposium, 1/1/2009
• Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): Preliminary results on toxicity and K-r...
  Cohen DJ, Ma H., Yuan Y., Hochman T., Hochster HS, Journal of Clinical Oncology, 2008 Annual Meeting Proceedings Part I, 5/20/2008
• Intraperitoneal(IP) 5'-fluoro-2'deoxyuridine(FUDR): Safety and outcome when administered prior to adjuvant chemoradiotherapy(chemoRT) following R0 resection for gastri...
  Cohen DJ, Ryan T, Newman E, Iqbal S, Liu M, Utate M, Moore S, Potmesil M, Hochster H, Muggia FM, Journal of Clinical Oncology, 2007 Annual Meeting Proceedings Part I, 6/20/2007
• Intraperitoneal (IP) 5’-fluoro-2’-deoxyuridine (FUDR): Safety and outcome when administered prior to standard adjuvant chemoradiotherapy (chemoRT) following R0 surgica...
  Cohen DJ, Newman E, Iqbal S, El-Khoueiry S, Hiotis S, Marcus S, Ryan T, Liu M, Chandra A, Muggia F, ASCO Gastrointestinal Cancers Symposium, 1/1/2007
• Randomized trial of low-dose interleukin-2 vs. cyclosporine A and interferon-Gamma after high dose chemotherapy with peripheral blood progenitor support in women with ...
  Cohen DJ, Vahdat LT, Zipin D, Lo KS, Frederick D, Donovan D, Sharpe E, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS, 27th Annual San Antonio Breast Cancer Symposium, 1/1/2004
• Join now to see all

Lectures

• Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic ... 
  2019 ASCO Annual Meeting - 6/1/2019
• A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. 
  2019 ASCO Annual Meeting - 6/1/2019
• “Multidisciplinary Management of Localized Gastroesophageal Junction Cancers” 
  1/16/2014
• “A Randomized Phase II Study of Vismodegib (GDC-0449), a hedgehog pathway inhibitor, combined with FOLFOX in patients with advanced gastric and gastroesophageal juncti... 
  Bethesda, MD - 10/15/2012
• “Targeting the Hedgehog Pathway: Role in Gastroesophageal Cancer and Clinical Implications of its Inhibition” 
  Marriott Marquis, NYC - 11/9/2011
• “Progress in Therapy of Advanced Colorectal Cancer." 
  3/9/2011
• “P8376: Randomized Phase II Trial of FOLFOX6 +/- GDC-0449 in Gastric and GE Junction Cancer.” 
  NYC - 5/14/2010
• “Chemotherapy for Advanced Gastric Cancer." 
  New York University Medical Center - 4/22/2010
• “Colorectal Cancer” Advanced Immunology: the Gastrointestinal System 
  3/30/2010
• “The Hedgehog Pathway: Rationale for its inhibition in GI Cancers.” 
  12/7/2009
• “Pancreatic Cancer: Medical Management of Early Stage Disease." 
  New York University School of Medicine - 12/3/2009
• "The Hedgehog Pathway: Rationale for its inhibition in GI cancers.” 
  Marriott Marquis, NYC - 11/11/2009
• “Updates from ASCO Program 2009.” 
  6/10/2009
• “Progress in Therapy of Advanced Pancreatic Cancer.” 
  5/19/2009
• Join now to see all